Purpose: We used gas chromatography mass spectrometry (GC-MS) and reviewed dynamics of bile acids every colorectal cancer occupation part as contrast with a healthy adults after enforcement by all at once analysis of bile acids in feces of a healthy adults and the colorectal cancer patients so that we clarified the details of a possibility of colorectal cancer outbreak participation of allo type bile acids.
Subjects: The fecal bile acid measurements were made in a colorectal cancer group consisting of 89 patients and a control group consisting of 103 healthy adults.
Methods: All at once analyzed bile acid in feces of a control group and colorectal cancer group by GC-MS. Student's t-test was used to test for significant differences.
Results: As for allo cholic acid (allo CA), allo deoxycholic acid (allo DCA), allo lithocholic acid (allo LCA) and ursodeoxycholic acid (UDCA) which was 4 ingredients of 12 bile acid ingredients out of feces of colorectal cancer group, it showed a significant high level tendency in colorectal cancer group. The following ingredient showed a tendency to significant high level in every colorectal cancer occupation part. Ascending colon: allo DCA and allo LCA. Transverse colon: allo LCA. Descending colon: UDCA. Sigmoid colon: allo DCA and allo LCA. Rectum: allo CA, allo DCA, allo LCA and UDCA.
Conclusion: The results suggested that the allo type secondary bile acids (allo DCA and allo LCA) are factors that are more strongly involved in colorectal carcinogenesis than DCA or LCA. It was particularly noteworthy that there was a tendency for the allo LCA values to be higher in both sexes (p<0.001-p< 0.005). The results suggested that allo LCA may be a factor involved in colorectal cancer at all sites, except cecum and descending colon. The results suggested that at high values UDCA may be a bodily defense reaction factor that is involved in suppression of carcinogenesis rather than a factor involved in carcinogenesis.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinoma.
Biomed Pharmacother
December 2024
Department of Pharmacy, College of Pharmacy, Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Gyeonggi-do 15588, Republic of Korea. Electronic address:
Colorectal malignancies associated with KRAS and TP53 mutations led us to investigate the effects of combination therapy targeting KRAS, MEK1, or PLK1 in colorectal cancer. MEK1 is downstream of RAS in the MAPK pathway, whereas PLK1 is a mitotic kinase of the cell cycle activated by MAPK and regulated by p53. Bioinformatics analysis revealed that patients with colorectal cancer had a high expression of MAP2K1 and PLK1.
View Article and Find Full Text PDFTHBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer.
Mol Cancer
December 2024
Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
Cancer-associated fibroblasts (CAFs) exert multiple tumor-promoting functions and are key contributors to drug resistance. The mechanisms by which specific subsets of CAFs facilitate oxaliplatin resistance in colorectal cancer (CRC) have not been fully explored. This study found that THBS2 is positively associated with CAF activation, epithelial-mesenchymal transition (EMT), and chemoresistance at the pan-cancer level.
View Article and Find Full Text PDFCorrection: Long non-coding RNA CCL14-AS suppresses invasiveness and lymph node metastasis of colorectal cancer cells by regulating MEP1A.
Cancer Cell Int
December 2024
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
KRAS inhibitors: resistance drivers and combinatorial strategies.
Trends Cancer
December 2024
Charité - Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address:
In 1982, the RAS genes HRAS and KRAS were discovered as the first human cancer genes, with KRAS later identified as one of the most frequently mutated oncogenes. Yet, it took nearly 40 years to develop clinically effective inhibitors for RAS-mutant cancers. The discovery in 2013 by Shokat and colleagues of a druggable pocket in KRAS paved the way to FDA approval of the first covalently binding KRAS inhibitors, sotorasib and adagrasib, in 2021 and 2022, respectively.
View Article and Find Full Text PDFShould endoscopic submucosal dissection be offered to patients with early colorectal cancer?
Surgery
December 2024
Department of Colorectal Surgery, Digestive Disease & Surgery Institute, Cleveland Clinic, Cleveland, OH. Electronic address:
Background: Endoscopic submucosal dissection is increasingly used to treat early-stage colorectal cancer. This study evaluated the feasibility of endoscopic submucosal dissection in this setting and the determinants of lymph node metastasis.
Methods: We reviewed patients who underwent colorectal endoscopic submucosal dissection for early-stage colorectal cancer at a tertiary center between 2011 and 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!